Glasses pen newspaper

Carl Zeiss Meditec Share

Investing in Carl Zeiss Meditec AG, is an investment in the future of health. We drive the development of leading-edge technology and make it available for applications in the field of: ophthalmology, neurosurgery, ENT surgery, dental applications and systems for intraoperative radiotherapy in the treatment of breast cancer.

Quotes, Charts & Orderbook

Security Identification Numbers of CZM Shares  
Stock exchange abbrevation AFX
ISIN DE0005313704
Reuters Identification Code (RIC) AFXG.F (exchange floor)
  AFXG.DE (XETRA)
Bloomberg AFX GR

Key Facts at a Glance

  • Basic Data
    ISIN DE0005313704
    Trading segment Prime Standard
    Designated Sponsors ODDO BHF Corporates & Markets AG
    Paying agent Commerzbank AG
    Share capital EUR 89,440,570.00
    Admitted capital EUR 89,440,570.00
    Category and nominal value No-par value bearer shares at a nominal value of EUR 1.00 per share
    Stock Markets Deutsche Börse, Frankfurt (XETRA and exchange floor, "Parkett")
    Regional stock exchanges in Berlin, Bremen, Düsseldorf, Hamburg, Munich and Stuttgart
    Capital measures

    23-Mar-2017:
    Increase of the share capital of EUR 89,309,610.00
    against cash contribution by EUR 8,130,960.00 (approx. 10%) to EUR
    89,440,570.00; subscription rights of shareholders were excluded.

    26-Oct-2006:
    Increase of the share capital of EUR 32,523,844.00 (divided into 32,523,844 no-par value shares) by EUR 48,785,766.00 to EUR 81,309,610.00 (divided into 81,309,610 no-par value shares); capital increase with subscription rights and against contributions in kind and cash contributions.

    10-May-2005:
    Increase of the share capital of EUR 29,682,182.00 against cash contribution by EUR 2,841,662.00 (approx. 10%) to EUR 32,523,844.00; subscription rights of shareholders were excluded.

    01-Feb-2005:
    Increase of the share capital of EUR 28,416,628.00 against contribution in kind by EUR 1,265,553.00 (4.45%) to EUR 29,682,182.00; subscription rights of shareholders were excluded; capital increase was part of the acquisition of the majority holding in IOLTech S.A.

    18-Sep-2003:
    Increase of the share capital of EUR 28,833,300.00 against cash contribution by EUR 2,583,329.00 (10%) to EUR 28,416,629.00; subscription rights of shareholders were excluded.
  • Dividend
    Development of the dividend
    Development of the dividend

    Development of the dividend

  • Key Share Data
      2021/22 2020/21 2019/20 2018/19 2017/18 2016/17
    XETRA
    Year-end price (EUR)1)
    		 107,45 166,05 108.00
         		 104.6
    		 72.5 44.17
    Year high (EUR)1) 191,05 199,05 121.40 108.7
    		 76.6 47.45
    Year low (EUR)1) 101,75 105,14 69.70 61.0
    		 44.85 31.00
    Year average (EUR) 141,67 142,65 98.18 81.80 56.91 39.70
    Daily order book turnover (XETRA) in fiscal year
    EUR 15.367.421 14.817.336 16.090.137 13.264.306
    		 4.988.993 3.430.556
    Shares 109.627 105.938 167.107
    		 162.154
    		 85.818
    		 86.412
    Number of shares as of 30. September (million shares) 89,4 89,4 89,4 89,4
    		 89,4 89,4
    Market capitalization as of 30. September (million EUR) 9.610,40 14.851,60 9.659,6
    		 9.355,5
    		 6.484,4
    		 3.950,1
    Earnings per share (EUR) 3,29 2,64 1,37 1,79
    		 1,41 1,57
    Dividend per share (EUR) 1,10 0,90 0.53) 0,653)
    		 0,552) 0,552)
    Dividend yield (%)1) 1,0 0,5 0,5 0,7 0,8 1.62

    1) End of fiscal year: 30. September.
    2) Amounts suggested by the Supervisory Board and the Executive Board of the Carl Zeiss Meditec AG.
    3) Amounts suggested by the Supervisory Board and the Executive Board of the Carl Zeiss Meditec AG.
    4) Until FY 2016/17 ratio of dividend per share to opening price for the respective fiscal year, from FY 2017/18 ratio of dividend per share to closing rate on 30 September.

     

  • Research Coverage
    Bank/Analyst Current Rating Date Price Target
    Deutsche Bank AG
    Falko Friedrichs    		 Buy 11-05-2023 150.00 €
    Bank of America Meryll Lynch
    Julien Ouaddour
    		 Neutral 10-05-2023 115.00 €
    HSBC
    Sezgi Oezener    		 Buy 10-05-2023 128.00 €
    LBBW
    Volker Stoll    		 Buy 09-05-2023 141.00 €
    UBS
    Graham Doyle    		 Buy 09-05-2023 148.00 €
    ALPHAVALUE
    Anas Patel    		 Buy 09-05-2023 165.00 €
    Hauck & Aufhäuser
    Alexander Galitsa    		 Buy 20-04-2023 175.00 €
    EQUI.TS GmbH
    Thomas Schießle    		 Buy 20-04-2023 176.00 €
    Berenberg Bank
    Beatrice Allen    		 Hold 20-04-2023 138.00 €
    ODDO BHF
    Daniel Wendorff    		 Neutral 20-04-2023 115.00 €
    KeplerCheuvreux
    Oliver Reinberg    		 Reduce 19-04-2023
    		 111.00 €
    Alster Research
    Harald Hof    		 Hold 13-03-2023 125.00 €
    DZ Bank
    Sven Kürten    		 Buy 06-03-2023 155.00 €
    Bankhaus Metzler
    Alexander Neuberger    		 Buy 10-01-2023 177.00 €
    Stifel (MAINFIRST Bank AG)
    Markus Gola    		 Buy 05-08-2022 165.00 €
    Morningstar
    Aaron Degagne    		   09-08-2021 64.00 €
    Nord/LB
    Holger Fechner    		 Buy 26-05-2021 172.00 €
    Montega AG
    Henrik Markmann
    		 Sell 26-01-2017 31.00 €

    Please note: Banks and securities firms use different terms for their equity ratings.The information contained in the table is based on publicly available sources that we consider reliable but for which we do not assume any liability.

    In particular, we do not guarantee that the information is complete, accurate or up-to-date. All ratings are based on opinions given by the analysts in question. These do not necessarily reflect the opinion of Carl Zeiss Meditec AG. The assessments may change at any time without prior notice. Exemption from liability applies to Carl Zeiss Meditec AG; it does not refer to the correct rendering of the information based on external sources, in particular public sources.

    Analyst assessments relating to Carl Zeiss Meditec AG shares are only revised each quarter and are therefore not continually updated.

  • Shareholder Structure

    Carl Zeiss Meditec AG's subscribed capital is composed of 89,440,570 ordinary shares, each with a theoretical par value of 1 € per share. The ZEISS Group holds around 59 % of the shares. According to our knowledge, the remaining 41 % are in free float.

For more information: Quotes, Charts & Orderbook